Drug intelligence / Profile preview

liposomal CHX-A''-DTPA-7.16.4

Development stage: Preclinical
Lead developer: National Cancer Institute
Modality: Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

liposomal CHX-A''-DTPA-7.16.4 is an experimental HER2-targeted immunoliposome construct designed for alpha-particle radioimmunotherapy. It consists of a 100-nm liposome surface-modified with the 7.16.4 monoclonal antibody, which specifically targets the HER2/neu (ErbB2) receptor. The construct incorporates the bifunctional chelator CHX-A''-DTPA to enable the stable conjugation of alpha-emitting radioisotopes, most notably Bismuth-213 ((213)Bi). This targeted delivery system is intended to treat micrometastatic disease, such as late-stage metastatic breast cancer, by delivering high-energy, short-range alpha radiation directly to tumor cells, thereby inducing lethal DNA double-strand breaks while sparing adjacent healthy tissue.

Other names: 7.16.4-conjugated liposomesHER2-targeted liposomal CHX-A''-DTPA

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on liposomal CHX-A''-DTPA-7.16.4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on liposomal CHX-A''-DTPA-7.16.4.

Explore the full profile